GlassScriptPhysician profile
Benjamin Taylor Seymour
NPI 1245004886
$1,842.56
in general payments reported to CMS, 2019-2025
15 companies · $708 in 2025
The $708 reported for 2025 was more than what 77% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,134 · 2025: $708.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,843.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,842.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $632.36 | 2024-2025 | |
| Amgen INC. | $224.31 | 2024-2025 | Otezla, Evenity, Repatha |
| Novo Nordisk INC | $219.54 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $203.98 | 2024 | Airsupra, Farxiga |
| Gilead Sciences, INC. | $176.69 | 2024 | Epclusa |
| Lilly USA, LLC | $94.64 | 2024-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $79.85 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $39.53 | 2024 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $38.91 | 2025 | Uzedy |
| Paratek Pharmaceuticals, INC. | $36.85 | 2024-2025 | Nuzyra |
| Exact Sciences Corporation | $31.06 | 2024 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $16.90 | 2024 | Abilify Asimtufii, Rexulti |
| Indivior INC. | $16.64 | 2024 | Sublocade |
| Pfizer INC. | $15.78 | 2024 | |
| Corcept Therapeutics | $15.52 | 2024 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Seymour listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.